Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.

Lalisang RI, Erdkamp FL, Rodenburg CJ, Knibbeler-van Rossum CT, Nortier JW, van Bochove A, Slee PH, Voest EE, Wils JA, Wals J, Loosveld OJ, Smals AE, Blijham GH, Tjan-Heijnen VC, Schouten HC.

Breast Cancer Res Treat. 2011 Jul;128(2):437-45. doi: 10.1007/s10549-011-1558-3. Epub 2011 May 17.

PMID:
21584666
2.

A core questionnaire for the assessment of patient satisfaction in academic hospitals in The Netherlands: development and first results in a nationwide study.

Kleefstra SM, Kool RB, Veldkamp CM, Winters-van der Meer AC, Mens MA, Blijham GH, de Haes JC.

Qual Saf Health Care. 2010 Oct;19(5):e24. doi: 10.1136/qshc.2008.030825. Epub 2010 Jun 24.

PMID:
20577001
3.

Career stage and work setting create different barriers for evidence-based medicine.

Swennen MH, van der Heijden GJ, Blijham GH, Kalkman CJ.

J Eval Clin Pract. 2011 Aug;17(4):775-85. doi: 10.1111/j.1365-2753.2010.01435.x. Epub 2010 Apr 23.

PMID:
20438602
4.

Importance of local aromatase activity in hormone-dependent breast cancer: a review.

de Jong PC, Blankenstein MA, van de Ven J, Nortier JW, Blijham GH, Thijssen JH.

Breast. 2001 Apr;10(2):91-9.

PMID:
14965567
5.
6.

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.

Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C, Stockmeyer B, Becker W, Eisenhut M, Steininger H, Deo YM, Blijham GH, Kalden JR, van de Winkel JG, Gramatzki M.

Br J Cancer. 2003 Dec 15;89(12):2234-43.

7.

The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease.

de Jong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH, Lu Q, Jelovac D, Brodie AM.

J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):149-55.

PMID:
14672735
8.

High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.

Wils J, Blijham GH, Wagener T, De Greve J, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B; EORTC Gastrointestinal Group.

Eur J Cancer. 2003 Feb;39(3):346-52.

PMID:
12565987
9.

The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.

Han SH, de Klerk JM, Tan S, van het Schip AD, Derksen BH, van Dijk A, Kruitwagen CL, Blijham GH, van Rijk PP, Zonnenberg BA.

J Nucl Med. 2002 Sep;43(9):1150-6.

10.

[Shortage in admission capacity for acute cases].

Blijham GH.

Ned Tijdschr Geneeskd. 2002 Apr 13;146(15):703-5. Dutch.

PMID:
11980369
11.

Aromatase and COX-2 expression in human breast cancers.

Brodie AM, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, DeJong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH.

J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):41-7.

PMID:
11850206
12.

Prediction of depression 6 months to 3 years after treatment of head and neck cancer.

de Leeuw JR, de Graeff A, Ros WJ, Blijham GH, Hordijk GJ, Winnubst JA.

Head Neck. 2001 Oct;23(10):892-8.

PMID:
11592237
13.

Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer.

de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA.

Eur J Cancer. 2001 Feb;37(3):332-9.

PMID:
11239754
14.

Interferon-alpha induced changes in CEA expression in patients with CEA-producing tumours.

Verhaar-Langereis MJ, Bongers V, de Klerk JM, van Dijk A, Blijham GH, Zonnenberg BA.

Eur J Nucl Med. 2000 Feb;27(2):209-13.

PMID:
10755728
15.
16.

Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.

Lalisang RI, Voest EE, Wils JA, Nortier JW, Erdkamp FL, Hillen HF, Wals J, Schouten HC, Blijham GH.

Br J Cancer. 2000 Jun;82(12):1914-9.

17.

Pretreatment factors predicting quality of life after treatment for head and neck cancer.

de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA.

Head Neck. 2000 Jul;22(4):398-407.

PMID:
10862025
18.

[Adjuvant systemic therapy for patients with resectable breast cancer: guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology].

Bontenbal M, Nortier JW, Beex LV, Bakker P, Hupperets PS, Nooij MA, van Veelen H, Vreugdenhil G, Richel DJ, Blijham GH.

Ned Tijdschr Geneeskd. 2000 May 20;144(21):984-9. Dutch.

PMID:
10858788
19.

Anti-apoptotic phenotype is associated with decreased locoregional recurrence rate in breast cancer.

Jager JJ, Jansen RL, Arends JW, Joosten-Achjanie S, Volovics L, Schouten LJ, De Jong JM, Meyenfeldt MF, Blijham GH.

Anticancer Res. 2000 Mar-Apr;20(2B):1269-75.

PMID:
10810433
20.

Distress in MEN 2 family members and partners prior to DNA test disclosure. Multiple endocrine neoplasia type 2.

Grosfeld FJ, Lips CJ, Beemer FA, Blijham GH, Quirijnen JM, Mastenbroek MP, ten Kroode HF.

Am J Med Genet. 2000 Mar 6;91(1):1-7.

PMID:
10751081
21.

Negative and positive influences of social support on depression in patients with head and neck cancer: a prospective study.

De Leeuw JR, De Graeff A, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA.

Psychooncology. 2000 Jan-Feb;9(1):20-8.

PMID:
10668056
22.

Radioimmunodiagnosis and therapy.

Verhaar-Langereis MJ, Zonnenberg BA, de Klerk JM, Blijham GH.

Cancer Treat Rev. 2000 Feb;26(1):3-10. Review.

PMID:
10660488
23.

Long-term quality of life of patients with head and neck cancer.

de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA.

Laryngoscope. 2000 Jan;110(1):98-106.

PMID:
10646723
24.

How will the hospital survive in the next millennium.

Blijham GH.

Neth J Med. 1999 Dec;55(6):257-60. No abstract available.

PMID:
10628170
25.

New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.

de Jong PC, Blijham GH.

Neth J Med. 1999 Aug;55(2):50-8. Review.

PMID:
10474272
26.

In vitro upregulation of carcinoembryonic antigen expression by combinations of cytokines.

Verhaar MJ, Damen CA, Zonnenberg BA, Blijham GH.

Cancer Lett. 1999 May 3;139(1):67-73.

PMID:
10408910
27.

Loco-regional recurrences after mastectomy in breast cancer: prognostic factors and implications for postoperative irradiation.

Jager JJ, Volovics L, Schouten LJ, de Jong JM, Hupperets PS, von Meyenfeldt MF, Schutte B, Blijham GH.

Radiother Oncol. 1999 Mar;50(3):267-75.

PMID:
10392812
28.

A prospective study on quality of life of laryngeal cancer patients treated with radiotherapy.

de Graeff A, de Leeuw RJ, Ros WJ, Hordijk GJ, Battermann JJ, Blijham GH, Winnubst JA.

Head Neck. 1999 Jul;21(4):291-6.

PMID:
10376747
29.

Prognostic value of cytokinetic parameters in lung cancer after in vivo bromodeoxyuridine labelling.

Tinnemans MM, Lenders MH, ten Velde GP, Blijham GH, Ramaekers FC, Schutte B.

Anticancer Res. 1999 Jan-Feb;19(1A):531-4.

PMID:
10226593
31.

A prospective study on quality of life of patients with cancer of the oral cavity or oropharynx treated with surgery with or without radiotherapy.

de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA.

Oral Oncol. 1999 Jan;35(1):27-32.

PMID:
10211307
32.

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJ, Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G, Van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J, Cote C, Blanc C, Hérait P, Bleiberg H.

Eur J Cancer. 1999 Jan;35(1):54-9.

PMID:
10211088
33.

186Re-etidronate in breast cancer patients with metastatic bone pain.

Han SH, Zonneberg BA, de Klerk JM, Quirijnen JM, van het Schip AD, van Dijk A, Blijham GH, van Rijk PP.

J Nucl Med. 1999 Apr;40(4):639-42.

34.
35.

Assessment of the quality of life of patients with advanced and end-stage cancer or serious infections with a symptom-based or an impact-based instrument.

Witteveen PO, Jacobs HM, van Groenestijn MA, Lodder AC, van Boxtel AH, Nieuwland M, Post MW, Touw-Otten FW, Blijham GH.

Support Care Cancer. 1999 Mar;7(2):64-70.

PMID:
10089084
36.

[Palliative treatment of bone metastases with bone-seeking radionuclides].

De Klerk JM, Zonnenberg BA, Huiskes AW, Han SH, Blijham GH, Van Rijk PP.

Ned Tijdschr Geneeskd. 1998 Nov 28;142(48):2618-22. Review. Dutch.

PMID:
10028362
37.

Angiogenesis inhibitors overcome tumor induced endothelial cell anergy.

Griffioen AW, Damen CA, Mayo KH, Barendsz-Janson AF, Martinotti S, Blijham GH, Groenewegen G.

Int J Cancer. 1999 Jan 18;80(2):315-9.

38.

Clinical research on antiangiogenic therapy.

Kuiper RA, Schellens JH, Blijham GH, Beijnen JH, Voest EE.

Pharmacol Res. 1998 Jan;37(1):1-16. Review.

PMID:
9503474
39.

Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors.

Hellwig SM, Damen CA, van Adrichem NP, Blijham GH, Groenewegen G, Griffioen AW.

Cancer Lett. 1997 Dec 9;120(2):203-11.

PMID:
9461038
40.

Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease.

Los M, Aarsman CJ, Terpstra L, Wittebol-Post D, Lips CJ, Blijham GH, Voest EE.

Ann Oncol. 1997 Oct;8(10):1015-22.

41.

The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer.

Hupperets PS, Volovics L, Schouten LJ, Jager JJ, Schouten HC, Hillen HF, Blijham GH.

Am J Clin Oncol. 1997 Dec;20(6):546-51.

PMID:
9391537
42.

CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells.

Griffioen AW, Coenen MJ, Damen CA, Hellwig SM, van Weering DH, Vooys W, Blijham GH, Groenewegen G.

Blood. 1997 Aug 1;90(3):1150-9.

PMID:
9242547
43.

Should patients with advanced colorectal cancer be treated with chemotherapy?

Blijham GH, Labianca R, Bleiberg H.

Eur J Cancer. 1997 May;33(6):815-24. No abstract available.

PMID:
9291799
44.

Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.

De Klerk JM, Zonnenberg BA, Blijham GH, Van Het Schip AD, Hoekstra A, Han SH, Quirijnen JM, Van Dijk A, Van Rijk PP.

Anticancer Res. 1997 May-Jun;17(3B):1773-7. Review.

PMID:
9179233
45.

Microvessel density and outcome of adjuvant treatment of breast cancer patients.

Voest EE, Blijham GH.

Cancer J Sci Am. 1997 May-Jun;3(3):184-5. No abstract available.

PMID:
9161785
46.

Prognostic significance of etiological risk factors in early breast cancer.

Schouten LJ, Hupperets PS, Jager JJ, Volovics L, Wils JA, Verbeek AL, Blijham GH.

Breast Cancer Res Treat. 1997 May;43(3):217-23.

PMID:
9150901
47.

Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.

Lalisang RI, Wils JA, Nortier HW, Burghouts JT, Hupperets PS, Erdkamp FL, Schouten HC, Blijham GH.

J Clin Oncol. 1997 Apr;15(4):1367-76.

PMID:
9193328
48.

[Microscopic tumor embolisms in metastasized breast carcinoma].

van de Ven PJ, de Jong PC, Jansen GH, Blijham GH.

Ned Tijdschr Geneeskd. 1997 Mar 15;141(11):536-40. Dutch.

PMID:
9190512
49.

Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.

Moers AM, Landsvater RM, Schaap C, Jansen-Schillhorn van Veen JM, de Valk IA, Blijham GH, Höppener JW, Vroom TM, van Amstel HK, Lips CJ.

Am J Med. 1996 Dec;101(6):635-41.

PMID:
9003111
50.

Euthanasia, physician-assisted suicide and palliative care.

Blijham GH.

Ann Oncol. 1996 Nov;7(9):879-82. No abstract available.

Supplemental Content

Loading ...
Support Center